Learn about side effects, cost, uses, and more for Venclexta (venetoclax). It's a prescription drug that treats cancer, including acute myeloid leukemia (AML).

About VENCLEXTA® (venetoclax) VENCLEXTA® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein.

Learn about Venclexta’s common, mild, and serious side effects and how to manage them. Venclexta (venetoclax) is a prescription drug used to treat acute myeloid leukemia (AML) and other cancers.

Venclexta, which is used to treat acute myeloid leukemia and other cancers, can cause side effects. Learn about its mild and serious side effects.

This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to ...

Venclexta is a targeted therapy for cancer. Here’s how it treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

VENCLEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis. VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche.

Venclexta is a prescription drug used to treat certain blood cancers. Learn how to lower long-term costs and more.

Venclexta, a first-in-class BCL2 inhibitor, is currently approved in combination with rituximab for the treatment of patients with CLL or small lymphocytic lymphoma (SLL), with or without 17p ...

VENCLEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis. VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche.